Difamilast - Otsuka Pharmaceutical

Drug Profile

Difamilast - Otsuka Pharmaceutical

Alternative Names: MM 36; MM36-Medimetriks Pharmaceuticals; OPA-15406

Latest Information Update: 30 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otsuka Pharmaceutical Development & Commercialization
  • Developer Medimetriks Pharmaceuticals; Otsuka Pharmaceutical Development & Commercialization
  • Class Benzamides; Oxazoles; Skin disorder therapies
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis

Most Recent Events

  • 30 Jan 2018 Chemical structure information added
  • 06 Sep 2017 Medimetriks Pharmaceuticals announces intention to submit NDA to US FDA for Atopic dermatitis in the second half of 2019
  • 06 Sep 2017 Efficacy and adverse events data from the phase II MUSE trial in Atopic dermatitis released by Medimetriks Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top